The Phase 3 clinical trials SURPASS trials In SURPASS-1 , all three tirzepatide doses (5,10,15mg) demonstrated statistically significant and clinically meaningful improvements in A1C and body weight reductions compared to placebo
Early trial results have shown promising outcomes in both weight reduction and metabolic improvements, highlighting mazdutides potential as a next-generation therapy
Those taking tirzepatide with insulin or sulfonylureas should be particularly aware of hypoglycaemia risk while driving
Appetite suppression is more potent here, and numerous people experience a weight loss of 0.5 to 1.5 kgs (1 to 3 lbs) per week once the appropriate dose is achieved
Edmondson DA, Xia P, McNally Keehn R, Dydak U, Keehn B
If you want help deciding between options, the Health Quiz can be a helpful starting point